Long-Term Evaluation of Cross-Sex Hormone Treatment in Transsexual Persons

Journal of Sexual Medicine

Volumn 9, Issue 10, 2012, Pages 2641-2651

  Wierckx, Katrien ^a   Mueller, Sven ^b   Weyers, Steven ^a   Van Caenegem, Eva ^a   Roef, Greet ^a   Heylens, Gunter ^a   T'Sjoen, Guy ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Gender Identity Disorder; Hormone Therapy; Osteoporosis; Side Effects; Thrombosis; Transsexualism

Indexed keywords

CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; SEX HORMONE; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; ARTICLE; BONE DENSITY; CARDIOVASCULAR RISK; CROSS SEX HORMONE THERAPY; DEEP VEIN THROMBOSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOPOROSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; SEX REASSIGNMENT; SPONDYLOSIS; TRANSIENT ISCHEMIC ATTACK; TRANSSEXUALISM; TREATMENT OUTCOME; ULCER;

EID: 84867396807     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02876.x     Document Type: Article

References (58)

1. De Cuypere G, T'Sjoen G, Beerten R, Selvaggi G, De Sutter P, Hoebeke P, Monstrey S, Vansteenwegen A, Rubens R. Sexual and physical health after sex reassignment surgery. Arch Sex Behav 2005;34:679-90.
2. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Meyer WJ 3rd, Spack NP, Tangpricha V, Montori VM. Endocrine treatment of transsexual persons: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132-54.
3. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people. A review of treatment regimes, outcomes and adverse effects. J Clin Endocrinol Metab 2003;88:3467-73.
4. Tangpricha V, Ducharme SH, Barber TW, Chipkin SR. Endocrinologic treatment of gender identity disorders. Endocr Pract 2003;9:12-21.
5. Gooren L. Hormone treatment of the adult transsexual patient. Horm Res 2005;64(2 suppl):31-6.
6. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. J Sex Med 2008;5:765-76.
7. Gooren L. Care of transsexual persons. N Engl J Med 2011;364:1251-7.
8. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25.
9. Weyers S, Elaut E, De Sutter P, Gerris J, T'Sjoen G, Heylens G, De Cuypere G, Verstraelen H. Long-term assessment of the physical, mental and sexual health among transsexual women. J Sex Med 2009;6:752-60.
10. T'Sjoen G, Weyers S, Taes Y, Lapauw B, Toye K, Goemaere S, Kaufman JM. Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. J Clin Densitom 2009;12:306-13.
11. Wierckx K, Van Caenegem E, Elaut E, Vandepeer F, Dedecker D, Toye K, Weyers S, Hoebeke P, Monstrey S, De Cuypere G, T'Sjoen G. Quality of life and sexual health after sex reassignment surgery in transsexual men. J Sex Med 2011;8:3379-88.
12. Wierckx K, Elaut E, Van Caenegem E, Van de peer F, Dedecker D, Vanhoudenhove E, T'Sjoen G. Sexual desire in female-to-male transsexual persons: An exploration of the role of testosterone replacement. Eur J Endocrinol 2011;165:331-7.
13. Wierckx K, Van Caenegem E, Pennings G, Elaut E, Van de peer F, Dedecker D, Weyers S, De Sutter P, T'Sjoen G. Reproductive wish in transsexual men. Hum Reprod 2012;27:483-7.
14. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston Jr CC, Lindsay R. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-90.
15. Szulc P, Claustrat B, Munoz F, Marchand F, Delmas PD. Assessment of the role of 17 beta-oestradiol in bone metabolism in men: Does the assay technique matter ? The MINOS study. Clin Endodocrinol 2001;61:447-57.
16. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
17. Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997;47:337-42.
18. Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: Lessons from female-to-male transsexuals (FTM) treated with pharmacological testosterone therapy. J Sex Med 2010;7:3758-64.
19. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78.
20. Coviello A, Kaplan B, Lakshman K, Chen T, Singh A, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008;93:914-5.
21. Duvigneaud N, Wijndaele K, Matton L, Deruemaeker P, Philippaerts R, Lefevre J, Thomis M, Duquet W. Socio-economic and lifestyle factors associated with overweight in Flemisch adult men and women. BMC Public Health 2007;7:23-33.
22. Belgische Gezondheidenquête. Rapport 2- leefstijl en preventie. 2008.
23. Duprez D, Helshoecht PV, Eynde WV, Leeman M. Prevalence of hypertension in the adult population of Belgium: Report of a worksite study. J Hum Hypertens 2002;16:47-52.
24. De Henauw S, De Bacquer D, de Smet P, Kornitzer M, De Backer G. Trends and regional differences in coronary risk factors in two areas in Belgium: Final results from the MONICA Ghent-Charleroi Study. J Cardiovasc Risk 2000;7:347-57.
25. Mullie P, Clarys P, Hulens M, Vansant G. Distribution of cardiovascular risk factors in Belgian army men. Arch Environ Contam Toxicol 2010;65:135-9.
26. Asscheman H, Giltay EJ, Megens J, de Ronde W, Trotsenburg MA. A long term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011;164:635-42.
27. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst F, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35.
28. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ 2008;336:1227-36.
29. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestagens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423.
30. Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, Rosing J. Venous thrombosis and changes of hemostatic variables during cross-sex treatment in transsexual people. J Clin Endocrinol Metab 2003;88:5723-9.
31. Buntinx F, Devroey D, Van Casteren V. The incidence of stroke and transient ischaemic attacks is falling: A report from the Belgian sentinel stations. Br J Gen Pract 2002;52:813-7.
32. Kemmeren J, Tanis B, van den Bosch M, Bollen E, Helmerhorst F, van der Graaf Y, Rosendaal F, Algra A. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: Oral contraceptives and the risk of ischemic stroke. Stroke 2002;33:1202-8.
33. Sare G, Gray L, Bath P. Association between hormone replacement therapy and subsequent arterial and venous vascular events: A meta-analysis. Eur Heart J 2008;29:2031-41.
34. Lindenstrøm E, Boysen G, Nyboe J. Life style factors and risk of cerebrovascular disease in women. Copenhagen City Heart Study Stroke 1993;24:1468-72.
35. Asscheman H, Gooren LJG, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender treatment. Metabolism 1989;38:869-73.
36. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg 1995;82:341.
37. Hage JJ, Dekker JJ, Karim RB, Verheijen RH, Bloemena E. Ovarian cancer in female-to-male transsexuals: Report of two cases. Gyanecol Oncol 2000;76:413-45.
38. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008;159:197-202.
39. Weyers S, Decaestecker K, Verstraelen H, Monstrey S, T'Sjoen G, Gerris J, Hoebeke P, Villeirs G. Clinical and transvaginal sonographic evaluation of the prostate in transsexual women. Urology 2009;74:191-6.
40. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckman W, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005;113:586-92.
41. Ruetsche AG, Kneubuehl R, Birkhaeuser MH, Lippuner K. Cortical and trabecular BMD in transsexuals after long-term cross-sex hormone treatment: A cross-sectional study. Osteoporos Int 2005;16:791-8.
42. Turner A, Chen TC, Barber TW, Malabanan AO, Holick MF, Tangpricha V. Testosterone increases bone mineral density in female-to-male transsexuals: A case series of 15 subjects. Clin Endocrinol (Oxf) 2004;61:560-6.
43. Mueller A, Haenerle L, Zollver H, Claasen T, Kronawitter D, Oppelt PG, Cupisti S, Beckman MW, Dittrich R. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med 2010;7:3190-8.
44. Van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J. Long-term follow up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 1998;48:347-54.
45. Mueller A, Dittrich R, Binder H, Binder H, Kuehnel W, Maltaris T, Hoffmann I, Beckmann MW. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone antagonist in the absence of testosterone. Eur J Endocrinol 2005;153:107-13.
46. Lips P, Asscheman H, Uitewaal P, Netelenbos JC, Gooren L. The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. J Bone Miner Res 1989;4:657-62.
47. Haraldsen IR, Haug E, Falch J, Egeland T, Opjordsmoen S. Cross-sex pattern of bone mineral density in early onset gender identity disorder. Horm Behav 2007;52:334-43.
48. Sosa M, Jodar E, Arbelo E, Domínguez C, Saavedra P, Torres A, Salido E, de Tejada MJ, Hernández D. Bone mass, bone turnover, vitamin D and estrogen receptor gene polymorphism in male-to-female transsexuals: Effect of estrogenic treatment on bone metabolism of the male. J Clin Densitom 2003;6:297-304.
49. Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, Toye K, Kaufman JM, T'Sjoen G. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone 2008;43:1016-21.
50. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-7.
51. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer 2003;100:892-9.
52. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation therapy for prostate cancer. N Engl J Med 2005;104:1633-7.
53. Smith M, Boyce S, Moyneur E, Duh M, Raut M, Brandman J. Risk of clinical fracture after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006;175:136-9.
54. Gooren LJ. Clinical review: Ethical and medical considerations of androgen deprivation treatment of sex offenders. J Clin Endocrinol Metab 2011;96:3628-37.
55. Bauman A, Bull F, Chey T, Craig C, Ainsworth B, Sallis B, Bowles H, Hagstromer M, Sjostrom M, Pratt M, the IPS Group. The international prevalence study on physical activity: Results from 20 countries. Int J Behav Nutr Phys Act 2009;6:21-32.
56. Sjöström M, Oja P, Hagströmer M, Smith BJ, Bauman AE. Health-enhancing physical activity across European Union countries: The Eurobarometer study. J Public Health 2006;14:291-300.
57. Currie C, Roberts C, Morgan A, Smith R, Settertobulte W, Samdal O, Rasmussen V, eds. 2004. Young People's Health in Context: International report from the HBSC 2001/02 survey.
58. Nieder TO, Herff M, Cerwenka S, Preuss WF, Cohen-Kettenis PT, De Cuypere G, Haraldsen IR, Richter-Appelt H. Age of onset and sexual orientation in transsexual males and females. J Sex Med 2011;8:783-79.